Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients.

Michael R BolandÉanna J RyanTimothy NugentDarina GilroyMichael E KellyJohn KennedyAoife MaguireDhafir AlazawiTerence J BoyleElizabeth M Connolly

Published in: Journal of surgical oncology (2020)

Over 30% of ER+, PgR-, and HER- patients will have a breast pCR after NAC. PgR- is the only significant predictor of breast pCR/cRR in this tumor subtype. ER+, PgR-, and HER- patients should be considered for NAC.

Keyphrases

end stage renal disease
estrogen receptor
neoadjuvant chemotherapy
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
transcription factor
radiation therapy
squamous cell carcinoma
patient reported outcomes